| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
A whole-genome association study of major determinants for host control of HIV-1.
|
Science
|
2007
|
15.19
|
|
2
|
Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases.
|
Lancet Neurol
|
2010
|
5.03
|
|
3
|
Common genetic variation and the control of HIV-1 in humans.
|
PLoS Genet
|
2009
|
3.68
|
|
4
|
Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management.
|
J Infect Dis
|
2005
|
3.52
|
|
5
|
Incidence and predictors of death, retention, and switch to second-line regimens in antiretroviral- treated patients in sub-Saharan African Sites with comprehensive monitoring availability.
|
Clin Infect Dis
|
2009
|
2.19
|
|
6
|
Risk of developing specific AIDS-defining illnesses in patients coinfected with HIV and hepatitis C virus with or without liver cirrhosis.
|
Clin Infect Dis
|
2009
|
1.95
|
|
7
|
A genotypic drug resistance interpretation algorithm that significantly predicts therapy response in HIV-1-infected patients.
|
Antivir Ther
|
2002
|
1.92
|
|
8
|
Clinical epidemiology and survival of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy: data from the Italian Registry Investigative Neuro AIDS (IRINA).
|
J Neurovirol
|
2003
|
1.70
|
|
9
|
Revised central nervous system neuropenetration-effectiveness score is associated with cognitive disorders in HIV-infected patients with controlled plasma viraemia.
|
Antivir Ther
|
2013
|
1.66
|
|
10
|
Tracing the HIV-1 subtype B mobility in Europe: a phylogeographic approach.
|
Retrovirology
|
2009
|
1.58
|
|
11
|
Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA).
|
AIDS
|
2002
|
1.52
|
|
12
|
Long-term survival and virus production in human primary macrophages infected by human immunodeficiency virus.
|
J Med Virol
|
2002
|
1.49
|
|
13
|
Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure.
|
AIDS Res Hum Retroviruses
|
2002
|
1.45
|
|
14
|
The effect of polymorphisms in candidate genes on the long-term risk of lipodystrophy and dyslipidemia in HIV-infected white patients starting antiretroviral therapy.
|
AIDS Res Hum Retroviruses
|
2011
|
1.45
|
|
15
|
Copy number variation of KIR genes influences HIV-1 control.
|
PLoS Biol
|
2011
|
1.44
|
|
16
|
Comparison of HIV-1 genotypic resistance test interpretation systems in predicting virological outcomes over time.
|
PLoS One
|
2010
|
1.33
|
|
17
|
Association study of common genetic variants and HIV-1 acquisition in 6,300 infected cases and 7,200 controls.
|
PLoS Pathog
|
2013
|
1.33
|
|
18
|
A novel methodology for large-scale phylogeny partition.
|
Nat Commun
|
2011
|
1.29
|
|
19
|
The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes.
|
J Acquir Immune Defic Syndr
|
2006
|
1.27
|
|
20
|
Comparative determination of HIV-1 co-receptor tropism by Enhanced Sensitivity Trofile, gp120 V3-loop RNA and DNA genotyping.
|
Retrovirology
|
2010
|
1.26
|
|
21
|
Naturally occurring hepatitis C virus (HCV) NS3/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy.
|
J Antimicrob Chemother
|
2012
|
1.21
|
|
22
|
Reduced rate of diagnostic positive detection of JC virus DNA in cerebrospinal fluid in cases of suspected progressive multifocal leukoencephalopathy in the era of potent antiretroviral therapy.
|
J Clin Microbiol
|
2005
|
1.20
|
|
23
|
Patient-reported and physician-estimated adherence to HAART: social and clinic center-related factors are associated with discordance.
|
J Gen Intern Med
|
2004
|
1.16
|
|
24
|
Declining prevalence of HIV-1 drug resistance in treatment-failing patients: a clinical cohort study.
|
Antivir Ther
|
2007
|
1.15
|
|
25
|
Virologic correlates of adherence to antiretroviral medications and therapeutic failure.
|
J Acquir Immune Defic Syndr
|
2002
|
1.14
|
|
26
|
Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years.
|
Arch Intern Med
|
2010
|
1.12
|
|
27
|
Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: 2 years of experience in routine clinical practice.
|
J Antimicrob Chemother
|
2009
|
1.12
|
|
28
|
Adherence to highly active antiretroviral therapy is better in patients receiving non-nucleoside reverse transcriptase inhibitor-containing regimens than in those receiving protease inhibitor-containing regimens.
|
AIDS
|
2003
|
1.11
|
|
29
|
Increasing clinical virulence in two decades of the Italian HIV epidemic.
|
PLoS Pathog
|
2009
|
1.10
|
|
30
|
Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA study group.
|
New Microbiol
|
2012
|
1.10
|
|
31
|
Prevalence of hypovitaminosis D and factors associated with vitamin D deficiency and morbidity among HIV-infected patients enrolled in a large Italian cohort.
|
J Acquir Immune Defic Syndr
|
2011
|
1.09
|
|
32
|
Rational use of antiretroviral therapy in low-income and middle-income countries: optimizing regimen sequencing and switching.
|
AIDS
|
2008
|
1.08
|
|
33
|
Impaired CD4 T-cell count response to combined antiretroviral therapy in antiretroviral-naive HIV-infected patients presenting with tuberculosis as AIDS-defining condition.
|
Clin Infect Dis
|
2011
|
1.07
|
|
34
|
Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group.
|
New Microbiol
|
2010
|
1.06
|
|
35
|
Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study).
|
J Antimicrob Chemother
|
2013
|
1.05
|
|
36
|
Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
|
Clin Infect Dis
|
2005
|
1.04
|
|
37
|
Interruption of highly active antiretroviral therapy in HIV clinical practice: results from the Italian Cohort of Antiretroviral-Naive Patients.
|
J Acquir Immune Defic Syndr
|
2005
|
1.02
|
|
38
|
Decline of CD4⁺ T-cell count before start of therapy and immunological response to treatment in antiretroviral-naive individuals.
|
AIDS
|
2011
|
1.01
|
|
39
|
Rules-based HIV-1 genotypic resistance interpretation systems predict 8 week and 24 week virological antiretroviral treatment outcome and benefit from drug potency weighting.
|
J Antimicrob Chemother
|
2009
|
1.01
|
|
40
|
Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study.
|
J Antimicrob Chemother
|
2011
|
1.01
|
|
41
|
Rapid HIV-RNA decline following addition of raltegravir and tenofovir to ongoing highly active antiretroviral therapy in a woman presenting with high-level HIV viraemia at week 38 of pregnancy.
|
J Antimicrob Chemother
|
2010
|
0.99
|
|
42
|
Characterization of JC virus in cerebrospinal fluid from HIV-1 infected patients with progressive multifocal leukoencephalopathy: insights into viral pathogenesis and disease prognosis.
|
J Neurovirol
|
2007
|
0.96
|
|
43
|
Discontinuation of Initial Antiretroviral Therapy in Clinical Practice: Moving Toward Individualized Therapy.
|
J Acquir Immune Defic Syndr
|
2016
|
0.95
|
|
44
|
Virological response to salvage therapy in HIV-infected persons carrying the reverse transcriptase K65R mutation.
|
Antivir Ther
|
2007
|
0.94
|
|
45
|
Clinical implications of HIV-1 drug resistance in the neurological compartment.
|
Scand J Infect Dis Suppl
|
2003
|
0.92
|
|
46
|
Impact of lamivudine on the risk of liver-related death in 2,041 HBsAg- and HIV-positive individuals: results from an inter-cohort analysis.
|
Antivir Ther
|
2006
|
0.92
|
|
47
|
CD4 cell-monitored treatment interruption in patients with a CD4 cell count > 500 x 106 cells/l.
|
AIDS
|
2005
|
0.92
|
|
48
|
A randomized controlled trial to evaluate antiretroviral salvage therapy guided by rules-based or phenotype-driven HIV-1 genotypic drug-resistance interpretation with or without concentration-controlled intervention: the Resistance and Dosage Adapted Regimens (RADAR) study.
|
Clin Infect Dis
|
2005
|
0.90
|
|
49
|
Predicting the magnitude of short-term CD4+ T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapy.
|
Antivir Ther
|
2010
|
0.89
|
|
50
|
Determinants of HIV drug resistance and public health implications in low- and middle-income countries.
|
Antivir Ther
|
2012
|
0.88
|
|
51
|
Evolution and predictors of HIV type-1 drug resistance in patients failing combination antiretroviral therapy in Italy.
|
Antivir Ther
|
2009
|
0.87
|
|
52
|
Symptomatic illness and low CD4 cell count at HIV seroconversion as markers of severe primary HIV infection.
|
PLoS One
|
2013
|
0.87
|
|
53
|
Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study).
|
Scand J Infect Dis
|
2013
|
0.86
|
|
54
|
Predictors of adverse outcomes in HIV-1-infected children receiving combination antiretroviral treatment: results from a DREAM cohort in sub-Saharan Africa.
|
Pediatr Infect Dis J
|
2014
|
0.86
|
|
55
|
Modulatory effects of the CCR5 antagonist maraviroc on microglial pro-inflammatory activation elicited by gp120.
|
J Neurochem
|
2011
|
0.85
|
|
56
|
Discontinuation of secondary prophylaxis for Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients: a randomized trial by the CIOP Study Group.
|
Clin Infect Dis
|
2003
|
0.85
|
|
57
|
Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons.
|
Clin Infect Dis
|
2013
|
0.85
|
|
58
|
Decreased plasma levels of darunavir/ritonavir in a vertically infected pregnant woman carrying multiclass-resistant HIV type-1.
|
Antivir Ther
|
2010
|
0.85
|
|
59
|
Highly active antiretroviral therapy and allogeneic CD34(+) peripheral blood progenitor cells transplantation in an HIV/HCV coinfected patient with acute myeloid leukemia.
|
Exp Hematol
|
2002
|
0.85
|
|
60
|
Darunavir/ritonavir and raltegravir coadministered in routine clinical practice: potential role for an unexpected drug interaction.
|
Pharmacol Res
|
2010
|
0.85
|
|
61
|
An outbreak of HIV-1 subtype G among Italian injecting drug users.
|
AIDS
|
2007
|
0.84
|
|
62
|
Tenofovir discontinuation could predispose to urolithiasis in atazanavir-treated patients.
|
J Infect
|
2011
|
0.83
|
|
63
|
Robust supervised and unsupervised statistical learning for HIV type 1 coreceptor usage analysis.
|
AIDS Res Hum Retroviruses
|
2009
|
0.83
|
|
64
|
Immune activation and microbial translocation in liver disease progression in HIV/hepatitis co-infected patients: results from the Icona Foundation study.
|
BMC Infect Dis
|
2014
|
0.83
|
|
65
|
Computational models for prediction of response to antiretroviral therapies.
|
AIDS Rev
|
2012
|
0.83
|
|
66
|
Clinical evaluation of Rega 8: an updated genotypic interpretation system that significantly predicts HIV-therapy response.
|
PLoS One
|
2013
|
0.82
|
|
67
|
Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients.
|
Vaccine
|
2011
|
0.82
|
|
68
|
High burden of transmitted HIV-1 drug resistance in Italian patients carrying F1 subtype.
|
J Antimicrob Chemother
|
2012
|
0.82
|
|
69
|
A prognostic model for estimating the time to virologic failure in HIV-1 infected patients undergoing a new combination antiretroviral therapy regimen.
|
BMC Med Inform Decis Mak
|
2011
|
0.82
|
|
70
|
Exposure to abacavir and biomarkers of cardiovascular disease in HIV-1-infected patients on suppressive antiretroviral therapy: a longitudinal study.
|
J Acquir Immune Defic Syndr
|
2012
|
0.81
|
|
71
|
Phylogenetic analysis provides evidence of interactions between Italian heterosexual and South American homosexual males as the main source of national HIV-1 subtype C epidemics.
|
J Med Virol
|
2014
|
0.81
|
|
72
|
Virologic response to lopinavir-ritonavir-based antiretroviral regimens in a multicenter international clinical cohort: comparison of genotypic interpretation scores.
|
Antimicrob Agents Chemother
|
2008
|
0.81
|
|
73
|
Virological suppression reduces clinical progression in patients with multiclass-resistant HIV type 1.
|
AIDS Res Hum Retroviruses
|
2009
|
0.81
|
|
74
|
Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy.
|
J Antimicrob Chemother
|
2013
|
0.81
|
|
75
|
Using a database of HIV patients undergoing genotypic resistance test after HAART failure to understand the dynamics of M184V mutation.
|
Antivir Ther
|
2003
|
0.80
|
|
76
|
Asymmetry of the regimen is correlated to self-reported suboptimal adherence: results from AdUCSC, a cohort study on adherence in Italy.
|
J Acquir Immune Defic Syndr
|
2010
|
0.80
|
|
77
|
The threshold bootstrap clustering: a new approach to find families or transmission clusters within molecular quasispecies.
|
PLoS One
|
2010
|
0.80
|
|
78
|
The influence of hepatitis C virus coinfection on the risk of lipid abnormalities in a cohort of HIV-1-infected patients after initiation of highly active antiretroviral therapy.
|
J Acquir Immune Defic Syndr
|
2004
|
0.80
|
|
79
|
HIV-1 subtype F1 epidemiological networks among Italian heterosexual males are associated with introduction events from South America.
|
PLoS One
|
2012
|
0.79
|
|
80
|
Low rate of virological failure and maintenance of susceptibility to HIV-1 protease inhibitors with first-line lopinavir/ritonavir-based antiretroviral treatment in clinical practice.
|
J Med Virol
|
2010
|
0.79
|
|
81
|
[Survival, progression to AIDS and immunosuppression in HIV-positive individuals before and after the introduction of the highly active antiretroviral therapy (HAART)].
|
Epidemiol Prev
|
2004
|
0.79
|
|
82
|
Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI.
|
BMC Infect Dis
|
2011
|
0.79
|
|
83
|
Incidence, timing, and determinants of bacterial pneumonia among HIV-infected patients: data from the ICONA Foundation Cohort.
|
J Acquir Immune Defic Syndr
|
2013
|
0.79
|
|
84
|
Combining epidemiological and genetic networks signifies the importance of early treatment in HIV-1 transmission.
|
PLoS One
|
2012
|
0.78
|
|
85
|
Prediction of early and confirmed virological response by genotypic inhibitory quotients for lopinavir in patients naïve for lopinavir with limited exposure to previous protease inhibitors.
|
J Clin Virol
|
2005
|
0.78
|
|
86
|
Superinfection with drug-resistant HIV is rare and does not contribute substantially to therapy failure in a large European cohort.
|
BMC Infect Dis
|
2013
|
0.78
|
|
87
|
Stochastic modelling of genotypic drug-resistance for human immunodeficiency virus towards long-term combination therapy optimization.
|
Bioinformatics
|
2008
|
0.77
|
|
88
|
Virological and immunological response to antiretroviral regimens containing maraviroc in HIV type 1-infected patients in clinical practice: role of different tropism testing results and of concomitant treatments.
|
AIDS Res Hum Retroviruses
|
2013
|
0.77
|
|
89
|
Lipid-lowering effect of tenofovir in HIV-infected patients.
|
J Antimicrob Chemother
|
2010
|
0.77
|
|
90
|
Standardized representation, visualization and searchable repository of antiretroviral treatment-change episodes.
|
AIDS Res Ther
|
2012
|
0.77
|
|
91
|
Declining tuberculosis and drug resistance rate among HIV-positive patients at an Italian teaching hospital in the era of highly active antiretroviral therapy.
|
J Acquir Immune Defic Syndr
|
2002
|
0.76
|
|
92
|
Local and global spatio-temporal dynamics of HIV-1 subtype F1.
|
J Med Virol
|
2013
|
0.76
|
|
93
|
Antiretroviral neuropenetration scores better correlate with cognitive performance of HIV-infected patients after accounting for drug susceptibility.
|
Antivir Ther
|
2014
|
0.76
|
|
94
|
Recommendations for the use of hepatitis C virus protease inhibitors for the treatment of chronic hepatitis C in HIV-infected persons. A position paper of the Italian Association for the Study of Infectious and Tropical Disease.
|
New Microbiol
|
2014
|
0.76
|
|
95
|
Effect of hepatitis C virus genotype on CD4+ T cell count in a cohort of antiretroviral-naive HIV-1-infected individuals.
|
J Infect Dis
|
2005
|
0.75
|
|
96
|
Triple-nucleoside regimens versus efavirenz.
|
N Engl J Med
|
2004
|
0.75
|
|
97
|
Is there a drug-drug interaction between darunavir/ritonavir and raltegravir?
|
J Acquir Immune Defic Syndr
|
2012
|
0.75
|
|
98
|
Trends and correlates of HIV-1 resistance among subjects failing an antiretroviral treatment over the 2003-2012 decade in Italy.
|
BMC Infect Dis
|
2014
|
0.75
|
|
99
|
Switch of predicted HIV-1 tropism in treated subjects and its association with disease progression.
|
Medicine (Baltimore)
|
2016
|
0.75
|
|
100
|
Genotypic resistance to lopinavir and fosamprenavir with or without ritonavir of clinical isolates from patients failing protease inhibitors-containing HAART regimens: prevalence and predictors.
|
Scand J Infect Dis
|
2007
|
0.75
|
|
101
|
Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2-year follow-up in HIV-infected patients.
|
Antivir Ther
|
2014
|
0.75
|
|
102
|
HIV-1 fitness landscape models for indinavir treatment pressure using observed evolution in longitudinal sequence data are predictive for treatment failure.
|
Infect Genet Evol
|
2013
|
0.75
|
|
103
|
HCMV infection in renal transplant recipients: a retrospective cohort study.
|
New Microbiol
|
2013
|
0.75
|
|
104
|
Virologic therapy response significantly correlates with the number of active drugs as evaluated using a LiPA HIV-1 resistance scoring system.
|
J Clin Virol
|
2004
|
0.75
|
|
105
|
Antiretroviral therapy in chronic liver disease: focus on HIV/HCV coinfection--statements of the First Italian Consensus Workshop.
|
AIDS Rev
|
2005
|
0.75
|
|
106
|
No pol mutation is associated independently with the lack of immune recovery in patients infected with HIV and failing antiretroviral therapy.
|
J Med Virol
|
2011
|
0.75
|
|
107
|
Lipid abnormalities in HIV-infected patients are not correlated with lopinavir plasma concentrations.
|
J Acquir Immune Defic Syndr
|
2004
|
0.75
|
|
108
|
Efficacy and tolerability of dolutegravir and two nucleos(t)ide reverse transcriptase inhibitors in HIV-1-positive, virologically suppressed patients.
|
AIDS
|
2017
|
0.75
|
|
109
|
A comparison between abacavir and efavirenz as the third drug used in combination with a background therapy regimen of 2 nucleoside reverse-transcriptase inhibitors in patients with initially suppressed viral loads.
|
J Infect Dis
|
2006
|
0.75
|
|
110
|
Optimizing HIV therapy. A consensus project on differences between cytidine analogues and regime compactness.
|
New Microbiol
|
2014
|
0.75
|
|
111
|
Interpretation of genotypic resistance to predict darunavir/ritonavir failure in antiretroviral experienced patients.
|
J Acquir Immune Defic Syndr
|
2012
|
0.75
|
|
112
|
The role of baseline HIV-1 RNA, drug resistance, and regimen type as determinants of response to first-line antiretroviral therapy.
|
J Med Virol
|
2014
|
0.75
|
|
113
|
Are mutations in HIV type-1 reverse transcriptase 245 codon predictive of abacavir hypersensitivity reaction?
|
Antivir Ther
|
2009
|
0.75
|